Back to top

Image: Bigstock

Top Ranked Growth Stocks to Buy for July 5th

Read MoreHide Full Article

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 5th:

TopBuild Corp. (BLD - Free Report) : This company that engages in the installation and distribution of insulation and other building products, which carries a Zacks Rank #1 (Strong Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 12.6% over the last 60 days.

TopBuild has a PEG ratio of 0.57 compared with 1.18 for the industry. The company possesses a Growth Score of B.

TopBuild Corp. PEG Ratio (TTM)

TopBuild Corp. PEG Ratio (TTM)

TopBuild Corp. peg-ratio-ttm | TopBuild Corp. Quote

Asure Software, Inc. (ASUR - Free Report) :This provider of cloud-based human capital management and workspace management solutions, which carries a Zacks Rank #1, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.7% over the last 60 days.

Asure Software has a PEG ratio of 0.70, compared with 1.69 for the industry. The company possesses a Growth Score of A.

Mercury General Corporation (MCY - Free Report) : This company that writes personal automobile insurance, which carries a Zacks Rank #1, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2% over the last 60 days.

Mercury General has a PEG ratio of 0.48, compared with 1.63 for the industry. The company possesses a Growth Score of A.

Cigna Corporation (CI - Free Report) : This health service organization, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.3% over the last 60 days.

Cigna has a PEG ratio of 0.81, compared with 1.30 for the industry. The company possesses a Growth Score of B.

See the full list of top ranked stocks here.

Learn more about the Growth score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>